Recruiting
Phase 1

ABBV-243

Sponsor:

AbbVie

Code:

NCT07306754

Conditions

Healthy Volunteers

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Accepted

Interventions

ABBV-243

Placebo

ABBV-243

Placebo

Study Details

Brief summary:

The objective of this study is to assess the safety, tolerability, pharmacokinetics and immunogenicity of either single ascending intravenous (IV) doses of ABBV-243 or single ascending subcutaneous (SC) doses of ABBV-243 in healthy adult participants (Part 1), and a single intravenous (IV) dose in healthy Asian adult volunteers (Part 2

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

Healthy Volunteers

Study ID

NCT07306754

Start date

Dec 17, 2025

Status verified date

Jan, 2026

Completion date

May, 2027

Anticipated

Primary completion date

May, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Individuals between 18 and 60 years of age inclusive at the time of Screening.
  • BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenth's decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • Females, Non-Childbearing Potential are eligible as defined by meeting the following criteria:

  • Permanent sterility due to a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
  • Non-surgical permanent infertility due to Mullerian agenesis, androgen insensitivity, or gonadal dysgenesis; investigator discretion should be applied to determining study entry.
  • Postmenopausal female who is age ≤ 55 years with no menses for 12 or more months without an alternative medical cause AND an FSH level ≥ 30 IU/L.
  • Postmenopausal female who is age > 55 years with no menses for 12 or more months without an alternative medical cause.
  • Females, Childbearing Potential are defined as all other females who do not meet the above criteria and must adhere to the following:

  • Must not be pregnant or breastfeeding.
  • Must agree to avoid pregnancy while taking study treatment(s) and for at least 200 days after the last dose of study treatment.
  • Must agree to use a contraceptive method listed below (as per local regulations) that is highly effective (with a failure rate of < 1% per year, when used consistently and correctly). Participants must provide documentation to the site.
  • Bilateral tubal occlusion/ligation.
  • Intrauterine device (IUD) to be inserted at least 30 days prior to Screening.
  • Intrauterine hormone-releasing system (IUS) to be inserted at least 30 days prior to Screening.
  • Part 2 only:

Healthy Japanese and Han Chinese male or female; between 18 and 60 years of age, inclusive at the time of Screening.

\- Han Chinese participants must be first- or second-generation Han Chinese of full Chinese parentage. First-generation participants are defined as those born in China to two parents and four grandparents also born in China of full Chinese descent. Second-generation participants are defined as those born outside of China to two parents and four grandparents born in China of full Chinese descent.

OR

\- Japanese participants must be first- or second-generation Japanese of full Japanese parentage. First-generation participants will have been born in Japan to two parents and four grandparents also born in Japan of full Japanese descent. Second-generation subjects born outside of Japan must have two parents and four grandparents born in Japan of full Japanese descent.

Exclusion Criteria:

  • History: of epilepsy, any clinically significant cardiovascular, respiratory (except mild asthma as a child), renal, endocrine, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.
  • Evidence of dysplasia or history of malignancy (including lymphoma and leukemia) other than successfully treated non-metastatic cutaneous squamous cell, basal cell carcinoma, or localized carcinoma in situ of the cervix.
  • History or evidence of active Tuberculosis (TB) disease or latent TB infection.

Study Design

Enrollment

66 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Group 1: ABBV-243 or Placebo

Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent, on Day 1

experimental: Group 2: ABBV-243 or Placebo

Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent, on Day 1

experimental: Group 3: ABBV-243 or Placebo

Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent, on Day 1

experimental: Group 4: ABBV-243 or Placebo

Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent. on Day 1

experimental: Group 5: ABBV-243 or Placebo

Participants will receive either a single subcutaneous (SC) dose of ABBV-243, or the placebo equivalent, on Day 1

experimental: Group 6: ABBV-243 or Placebo

Participants will receive either a single subcutaneous (SC) dose of ABBV-243, or the placebo equivalent, on Day 1

experimental: Group 7: ABBV-243 or Placebo

Han Chinese participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent. on Day 1

experimental: Group 8: ABBV-243 or Placebo

Japanese participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent. on Day 1

Interventions

ABBV-243

Intravenous (IV) Infusion

Placebo

Intravenous (IV) Infusion

ABBV-243

Subcutaneous (SC) Injection

Placebo

Subcutaneous (SC) Injection

Primary outcome measure

  • Number of Participants with Adverse Events (AEs) [ Time Frame: Up to Day 204 ]
  • Maximum Observed Serum Concentration (Cmax) of ABBV-243 [ Time Frame: Up to Day 204 ]
  • Time to Cmax (Tmax) of ABBV-243 [ Time Frame: Up to Day 204 ]
  • Area Under the Serum Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-243 [ Time Frame: Up to Day 204 ]
  • Area Under the Serum Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-243 [ Time Frame: Up to Day 204 ]
  • Terminal Phase Elimination Rate Constant (β) of ABBV-243 [ Time Frame: Up to Day 204 ]
  • Terminal Phase Elimination Half-Life (t1/2) of ABBV-243 [ Time Frame: Up to Day 204 ]
  • Anti-Drug Antibody (ADA) of ABBV-243 [ Time Frame: Up to Day 204 ]

Central Contacts and Locations

Central contacts

Locations

Acpru /Id# 279789

Recruiting

Grayslake, Illinois, United States, 60030

More Information

Sponsor

AbbVie

Last update posted

Jan 12, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by AbbVie on 2026-01-12.